Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

19 Dec 2012

Abstract excerpt

BACKGROUND: Interleukin-1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA). We assessed the efficacy and safety of canakinumab, a selective, fully human, anti-interleukin-1β monoclonal antibody, in two trials. METHODS: In trial 1, we randomly assigned patients, 2 to 19 years of age, with systemic JIA and active systemic features (fever; ≥2 active joints; C-reactive protein, >30 mg...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoimmune and Inflammatory Disorders Research
Share to Inflammasome and immune disorders
Share to Ocular Diseases and Behçet’s Syndrome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23252526
DOI: 10.1056/nejmoa1205099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic ArthritisPMID 23252526Read ↗

Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritisSemantic proximity Read ↗

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapySemantic proximity Read ↗

PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapySemantic proximity Read ↗

The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.Semantic proximity Read ↗

Treatment advances in systemic juvenile idiopathic arthritisSemantic proximity Read ↗

Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entitySemantic proximity Read ↗

New advances in juvenile idiopathic arthritis.Semantic proximity Read ↗

Anakinra in the Management of Adult-Onset Still’s Disease: A Single-Center ExperienceSemantic proximity Read ↗

Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approachesSemantic proximity Read ↗

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.Semantic proximity Read ↗

Current Medical Treatments for Juvenile Idiopathic ArthritisSemantic proximity Read ↗

Recognition and management of macrophage activation syndrome in juvenile arthritisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.